NR565 WEEK 1 CHAPTERS 2, 7, 8 STUDY QUESTIONS WITH CORRECT ANSWERS 2025

NR565 WEEK 1 CHAPTERS 2, 7, 8 STUDY
QUESTIONS WITH CORRECT ANSWERS 2025
ANpatient'sNnutritionalNintakeNandNlaboratoryNresultsNreflectNhypoalbuminemia.NThisNisNcriticalNtoNprescrib
ingNbecause:N-NCORRECTNANSWERN-DistributionNofNdrugsNtoNtargetNtissueNmayNbeNaffected.



DrugsNthatNhaveNaNsignificantNfirst-passNeffect:N-NCORRECTNANSWERN-
AreNrapidlyNmetabolizedNbyNtheNliverNandNmayNhaveNlittleNifNanyNdesiredNaction



TheNrouteNofNexcretionNofNaNvolatileNdrugNwillNlikelyNbeNthe:N-NCORRECTNANSWERN-Lungs



MedroxyprogesteroneN(DepoNProvera)NisNprescribedNintramuscularlyN(IM)NtoNcreateNaNstorageNreservoirNo
fNtheNdrug.NStorageNreservoirs:N-NCORRECTNANSWERN-
IncreaseNtheNlengthNofNtimeNaNdrugNisNavailableNandNactive



TheNNPNchoosesNtoNgiveNcephalexinNeveryN8NhoursNbasedNonNknowledgeNofNtheNdrug's:N-
NCORRECTNANSWERN-BiologicalNhalf-life




AzithromycinNdosingNrequiresNthatNtheNfirstNday'sNdosageNbeNtwiceNthoseNofNtheNotherN4NdaysNofNtheNpres
cription.NThisNisNconsideredNaNloadingNdose.NANloadingNdose:N-NCORRECTNANSWERN-
RapidlyNachievesNdrugNlevelsNinNtheNtherapeuticNrange



TheNpointNinNtimeNonNtheNdrugNconcentrationNcurveNthatNindicatesNtheNfirstNsignNofNaNtherapeuticNeffectNis
Nthe:N-NCORRECTNANSWERN-OnsetNofNaction




PhenytoinNrequiresNthatNaNtroughNlevelNbeNdrawn.NPeakNandNtroughNlevelsNareNdone:N-
NCORRECTNANSWERN-ToNdetermineNifNaNdrugNisNinNtheNtherapeuticNrange




ANlaboratoryNresultNindicatesNthatNtheNpeakNlevelNforNaNdrugNisNaboveNtheNminimumNtoxicNconcentration.N
ThisNmeansNthatNthe:N-NCORRECTNANSWERN-ConcentrationNwillNproduceNanNadverseNresponse



DrugsNthatNareNreceptorNagonistsNmayNdemonstrateNwhatNproperty?N-NCORRECTNANSWERN-
DesensitizationNorNdownregulationNwithNcontinuousNuse

, DrugsNthatNareNreceptorNantagonists,NsuchNasNbetaNblockers,NmayNcause:N-NCORRECTNANSWERN-
AnNexaggeratedNresponseNifNabruptlyNdiscontinued



FactorsNthatNaffectNgastricNdrugNabsorptionNinclude:N-NCORRECTNANSWERN-LipidNsolubilityNofNtheNdrug



DrugsNadministeredNviaNIV:N-NCORRECTNANSWERN-BeginNdistributionNintoNtheNbodyNimmediately



WhenNaNmedicationNisNaddedNtoNaNregimenNforNaNsynergisticNeffect,NtheNcombinedNeffectNofNtheNdrugsNis:N
-NCORRECTNANSWERN-GreaterNthanNtheNsumNofNtheNeffectsNofNeachNdrugNindividually



WhichNofNtheNfollowingNstatementsNaboutNbioavailabilityNisNtrue?



1.NBioavailabilityNissuesNareNespeciallyNimportantNforNdrugsNwithNnarrowNtherapeuticNrangesNorNsustained
-releaseNmechanisms.

2.NAllNbrandsNofNaNdrugNhaveNtheNsameNbioavailability.

3.NDrugsNthatNareNadministeredNmoreNthanNonceNaNdayNhaveNgreaterNbioavailabilityNthanNdrugsNgivenNonc
eNdaily.

4.NCombiningNanNactiveNdrugNwithNanNinertNsubstanceNdoesNnotNaffectNbioavailabilityN-
NCORRECTNANSWERN-

1.NBioavailabilityNissuesNareNespeciallyNimportantNforNdrugsNwithNnarrowNtherapeuticNrangesNorNsustained
-releaseNmechanisms.



WhichNofNtheNfollowingNstatementsNaboutNtheNmajorNdistributionNbarriersN(blood-brainNorNfetal-
placental)NisNtrue?



1.NWaterNsolubleNandNionizedNdrugsNcrossNtheseNbarriersNrapidly.

2.NTheNblood-brainNbarrierNslowsNtheNentryNofNmanyNdrugsNintoNandNfromNbrainNcells.

3.NTheNfetal-placentalNbarrierNprotectsNtheNfetusNfromNdrugsNtakenNbyNtheNmother.

4.NLipid-solubleNdrugsNdoNnotNpassNtheseNbarriersNandNareNsafeNforNpregnantNwomen.N-
NCORRECTNANSWERN-2.NTheNblood-

brainNbarrierNslowsNtheNentryNofNmanyNdrugsNintoNandNfromNbrainNcells.